…Cancer Center, “Synthetic Lethality of the Protexin and BRCA Complexes in Ovarian Cancer” Brooke Howitt, MD, Stanford University, “Identifying the Cell of Origin for High Grade Serous Carcinoma” Xiaowen Hu,…
…at higher risk for developing ovarian cancer. Risk factors include family history of ovarian cancer, mutations in genes known to increase risk (BRCA1 and BRCA2), diagnosis of pre-menopausal breast cancer…
…research findings into advances that can improve health outcomes in women at high-risk for ovarian cancer due to inherited mutations in the BRCA1 and BRCA2 genes. Dr. Yates has received…
…While the numbers of those tested increased over time, and especially accelerated after the approval of PARP inhibitors for BRCA1 and BRCA2 mutated chemotherapy-refractory ovarian cancer in December 2014, the…
…intravenous chemotherapy and stating that BRCA1/2 patients could benefit from the use of IP. All agreed that there are unresolved issues regarding the use of IP chemotherapy and much work…
…were identified for breast (n = 1) and ovarian (n = 2) cancers in BRCA1 mutation carriers and for breast cancer (n = 1) in BRCA2 mutation carriers. An epigenetic…
…114, and 172) resulted in longer PFS using intraperitoneal compared to intravenous chemotherapy and stating that BRCA1/2 patients could benefit from the use of IP. All agreed that there are…
…regardless of BRCA mutation status. Niraparib was first approved by the FDA for treatment of recurrent ovarian cancer in 2017. This most recent approval means ovarian cancer patients do not…
…and ovarian cancer risk in women with a family history of cancer. Breast and ovarian cancers have been linked to mutations in the BRCA1 and BRCA2 genes. The Ovarian Cancer…
A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2…
…for ovarian cancer continues to show promise. The SOLO-1 trial, for instance, illustrates that the PARP inhibitor olaparib can significantly improve progression-free survival for patients with an inherited BRCA mutation….
…repair machinery. In around half of all ovarian cancers — including those with mutations in the BRCA genes — cancer cells are defective in one type of repair mechanism. But…
Get email updates about research news, action alerts, and ways to join the fight.
